Nonstatin therapy obicetrapib promising for addressing unmet medical needs for high CV risk patients

Netherlands: CETP inhibitor drug obicetrapib has the potential to address the unmet medical need for patients at high cardiovascular risk, a recent study has concluded. 

The study, published in the journal Nature Medicine, showed the effectiveness of obicetrapib 5 mg and 10 mg as an additional treatment to high-intensity statins for a robust reduction in LDL-C, Apo B, non-HDL-C, and Lp(a) and increasing HDL-C and Apo A1 in comparison to placebo. This refutes the therapy that such cholesteryl ester transfer protein (CETP) inhibitor-driven effects would be diminished when used in addition to high-intensity statins. 

Current guidelines for managing high-cardiovascular-risk patients include aggressive goals for low-density lipoprotein cholesterol (LDL-C). Nonstatin options have limitations and statin therapy alone is not sufficient to reach goals. Stephen J. Nicholls, Victorian Heart Institute, Monash University, Clayton, Victoria, Australia, and colleagues tested the lipid-lowering effects of the CETP inhibitor drug obicetrapib in a randomized, double-blind, placebo-controlled trial. The trial was conducted in dyslipidaemic patients (n = 120, median LDL-C 88 mg dl−1) with background high-intensity statin treatment.